2,522 Shares in Illumina, Inc. $ILMN Purchased by Jefferies Financial Group Inc.

Jefferies Financial Group Inc. acquired a new position in Illumina, Inc. (NASDAQ:ILMN) in the 2nd quarter, Holdings Channel reports. The institutional investor acquired 2,522 shares of the life sciences company’s stock, valued at approximately $443,000.

A number of other institutional investors have also recently bought and sold shares of ILMN. Public Employees Retirement System of Ohio acquired a new stake in Illumina during the second quarter worth approximately $7,864,000. MASTERINVEST Kapitalanlage GmbH acquired a new position in Illumina in the 2nd quarter valued at $284,000. Stonehage Fleming Financial Services Holdings Ltd bought a new stake in shares of Illumina during the 2nd quarter valued at $918,000. Proficio Capital Partners LLC bought a new stake in shares of Illumina during the 2nd quarter valued at $941,000. Finally, Transamerica Financial Advisors LLC acquired a new stake in shares of Illumina during the 2nd quarter worth $152,000. Institutional investors own 89.42% of the company’s stock.

Analyst Ratings Changes

A number of brokerages recently commented on ILMN. Barclays raised their price target on Illumina from $145.00 to $160.00 and gave the stock an “underweight” rating in a research report on Friday, July 31st. TD Cowen upped their price objective on shares of Illumina from $192.00 to $210.00 and gave the stock a “hold” rating in a research report on Friday, July 31st. Citigroup increased their price objective on shares of Illumina from $95.00 to $113.00 and gave the stock a “sell” rating in a research note on Monday, August 3rd. Leerink Partners raised their target price on shares of Illumina from $175.00 to $210.00 and gave the company an “outperform” rating in a report on Friday, July 17th. Finally, Daiwa Securities Group upgraded shares of Illumina from a “neutral” rating to an “outperform” rating and set a $155.00 target price for the company in a research report on Thursday, May 14th. One investment analyst has rated the stock with a Strong Buy rating, eight have issued a Buy rating, six have issued a Hold rating and two have issued a Sell rating to the company’s stock. According to MarketBeat.com, the stock currently has an average rating of “Hold” and an average price target of $188.40.

Insiders Place Their Bets

In other news, SVP Christensen Jakob Wedel sold 1,033 shares of the firm’s stock in a transaction that occurred on Tuesday, August 18th. The shares were sold at an average price of $191.52, for a total value of $197,840.16. Following the sale, the senior vice president directly owned 14,023 shares in the company, valued at approximately $2,685,684.96. This trade represents a 6.86% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Keith A. Meister sold 457,858 shares of Illumina stock in a transaction that occurred on Tuesday, August 4th. The shares were sold at an average price of $200.10, for a total transaction of $91,617,385.80. Following the sale, the director directly owned 2,372,694 shares in the company, valued at $474,776,069.40. This trade represents a 16.18% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Over the last 90 days, insiders sold 1,799,688 shares of company stock valued at $379,517,231. 2.90% of the stock is currently owned by corporate insiders.

Illumina Trading Down 0.9%

Shares of ILMN stock opened at $213.63 on Tuesday. Illumina, Inc. has a fifty-two week low of $88.00 and a fifty-two week high of $231.81. The stock’s fifty day moving average price is $195.10 and its two-hundred day moving average price is $156.54. The company has a debt-to-equity ratio of 0.53, a quick ratio of 1.40 and a current ratio of 1.80. The company has a market cap of $32.26 billion, a PE ratio of 39.86, a P/E/G ratio of 3.03 and a beta of 1.44.

Illumina (NASDAQ:ILMN) last posted its quarterly earnings results on Thursday, July 30th. The life sciences company reported $1.31 EPS for the quarter, topping analysts’ consensus estimates of $1.23 by $0.08. Illumina had a return on equity of 29.84% and a net margin of 18.36%.The company had revenue of $1.16 billion during the quarter, compared to analysts’ expectations of $1.13 billion. During the same quarter in the previous year, the firm earned $1.19 EPS. Illumina’s revenue was up 9.4% on a year-over-year basis. Illumina has set its FY 2026 guidance at 5.300-5.400 EPS. Equities analysts predict that Illumina, Inc. will post 5.36 EPS for the current fiscal year.

About Illumina

Illumina, Inc (NASDAQ: ILMN) is a global life sciences company that develops, manufactures and markets integrated systems for the analysis of genetic variation and function. Headquartered in San Diego, California and founded in 1998, Illumina offers a range of sequencing and array-based technologies used by academic researchers, clinical laboratories, pharmaceutical and biotechnology companies, consumer genomics firms and agricultural researchers to enable discovery, translational research and clinical applications.

The company’s product portfolio includes next-generation sequencing (NGS) platforms and associated consumables, microarrays for genotyping and methylation analysis, library preparation kits and targeted assays.